Zoledronic acid decreases bone formation without causing osteocyte death in mice

Archives of Oral Biology

Volumn 54, Issue 9, 2009, Pages 851-856

  Huja, S S ^a   Fernandez, S A ^a   Phillips, Christina ^a   Li, Y ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Bisphosphonate; Bone labels; Osteocyte; Osteonecrosis; Viability

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CALCEIN; DIAGNOSTIC AGENT; FLUORESCEIN DERIVATIVE; FLUORESCENT DYE; IMIDAZOLE DERIVATIVE; LACTATE DEHYDROGENASE; ZOLEDRONIC ACID;

ANIMAL; ARTICLE; BONE DEVELOPMENT; BONE NECROSIS; C57BL MOUSE; CELL DEATH; CELL SURVIVAL; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; FEMUR; JAW; MALE; MANDIBLE; MAXILLA; MOUSE; OSTEOCYTE; PATHOLOGY;

ALVEOLAR PROCESS; ANIMALS; BONE DENSITY CONSERVATION AGENTS; CELL DEATH; CELL SURVIVAL; DIPHOSPHONATES; FEMUR; FLUORESCEINS; FLUORESCENT DYES; IMIDAZOLES; L-LACTATE DEHYDROGENASE; MALE; MANDIBLE; MAXILLA; MICE; MICE, INBRED C57BL; OSTEOCYTES; OSTEOGENESIS; OSTEONECROSIS;

MUS;

EID: 67650729326     PISSN: 00039969     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archoralbio.2009.06.002     Document Type: Article

References (30)

1. Allen M.R., Iwata K., Phipps R., and Burr D.B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone (2006)
2. Allen M.R., Iwata K., Sato M., and Burr D.B. Raloxifene enhances vertebral mechanical properties independent of bone density. Bone (2006)
3. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., and Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27 (2000) 687-694
4. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., and Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100 (1997) 1475-14780
5. Plotkin L.I., Aguirre J.I., Kousteni S., Manolagas S.C., and Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280 8 (2005) 7317-7325
6. Rodan G.A., and Reszka A.A. Osteoporosis and bisphosphonates. J Bone Joint Surg 85-A Suppl. 3 (2003) 8-12
7. Brooks J.K., Gilson A.J., Sindler A.J., Ashman S.G., Schwartz K.G., and Nikitakis N.G. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2007)
8. Pazianas M., Miller P., Blumentals W.A., Bernal M., and Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29 8 (2007) 1548-1558
9. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 34 (2005) 8580-8587
10. Hoff A.O., Toth B.B., Altundag K., Johnson M.M., Warneke C.L., Hu M., et al. The frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res (2008)
11. Migliorati C.A., Siegel M.A., and Elting L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7 6 (2006) 508-514
12. Statz T.A., Guthmiller J.M., Humbert L.A., and Johnson G.K. Intravenous bisphosphonate-associated osteonecrosis of the jaw. J Periodontol 78 11 (2007) 2203-2208
13. Allen M.R., and Burr D.B. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 66 5 (2008) 987-994
14. Stepan J.J., Alenfeld F., Boivin G., Feyen J.H., and Lakatos P. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 37 4 (2003) 225-238
15. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 12 Suppl. (2000) 2961-2978
16. Iwata K., Li J., Follet H., Phipps R.J., and Burr D.B. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone (2006)
17. Hardt A.B. Bisphosphonate effects on alveolar bone during rat molar drifting. J Dent Res 67 11 (1988) 1430-1433
18. Meta I.F., Fernandez S.A., Gulati P., and Huja S.S. Alveolar process anabolic activity in C3H/HeJ and C57BL/6J inbred mice. J Periodontol 79 7 (2008) 1255-1262
19. Meta I.F., Fernandez S.A., Gulati P., and Huja S.S. Adaptations in the mandible and appendicular skeleton of high and low bone density inbred mice. Calcif Tissue Int 81 2 (2007) 107-113
20. Thudi N.K., Martin C.K., Nadella M.V., Fernandez S.A., Werbeck J.L., Pinzone J.J., et al. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. Prostate 68 10 (2008) 1116-1125
21. Phillips C.A., Hughes D.R., and Huja S.S. Modifications of the lactate dehydrogenase assay, a histochemical determinant of osteocyte viability-a qualitative study. Acta Histochem 111 2 (2009) 166-171
22. Parfitt A.M. Stereologic basis of bone histomorphometry: theory of quantitative microscopy and reconstruction of the third dimension. In: Recker R.R. (Ed). Bone histomorphometry: techniques and interpretation (1983), CRC Press, Inc., Boca Raton, FL 54-87
23. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomoprhometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2 (1987) 595-610
24. Sonis S.T., Watkins B.A., Lyng G.D., Lerman M.A., and Anderson K.C. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol (2008)
25. Plotkin L.I., Mathov I., Aguirre J.I., Parfitt A.M., Manolagas S.C., and Bellido T. Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases, and ERKs. Am J Physiol Cell Physiol 289 3 (2005) C633-C643
26. Noble B.S., and Reeve J. Osteocyte function, osteocyte death and bone fracture resistance. Mol Cell Endocrinol 159 1-2 (2000) 7-13
27. Huja S.S., Fernandez S.A., Hill K.J., and Li Y. Remodeling dynamics in the alveolar process in skeletally mature dogs. Anat Rec A: Discov Mol Cell Evol Biol 288 12 (2006) 1243-1249
28. Ferguson V.L., Ayers R.A., Bateman T.A., and Simske S.J. Bone development and age-related bone loss in male C57BL/6J mice. Bone 33 3 (2003) 387-398
29. Stein M.S., Thomas C.D., Feik S.A., Wark J.D., and Clement J.G. Bone size and mechanics at the femoral diaphysis across age and sex. J Biomech 31 12 (1998) 1101-1110
30. Malmgren B., Astrom E., and Soderhall S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 37 4 (2008) 196-200